Implications for Immunotherapy of Viral Infections

  • Mayra Lopez-Cepero
  • Steven Specter
  • John Hadden
Part of the Infectious agents and pathogenesis book series (IAPA)


That host-defense mechanisms control viral infection and eventually limit the spread of disease has been recognized for many years. Preceding modern medicine, Chinese physicians in the eleventh century observed that the inhalation of smallpox crusts prevented the subsequent occurrence of disease. Later, in the eighteenth century in England, variolation was practiced by Lady Montagu as a primitive form of immunization to protect against smallpox.


Respiratory Syncytial Virus Newcastle Disease Virus Acquire Immune Deficiency Syndrome Rabies Virus Natural Killer Cell Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hadden, J. W., C. Lopez, R. J. O’Reilly, and E. M. Hadden, Levamisole and inosiplex: Antiviral agents with immunopotentiating action, Ann. NY Acad. Sci. 284:139–152 (1977).PubMedCrossRefGoogle Scholar
  2. 2.
    Wainberg, M. A., S. Vydelingum, and R. G. Margolese, Viral inhibition of lymphocyte mitogenesis: Interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same, J. Immunol. 130:2372– 2378 (1983).PubMedGoogle Scholar
  3. 3.
    Specter, S., and J. W. Hadden, New approaches to immunotherapy: Thymomimetic drugs, Spnger Semin. Immunopathol. 61:1–10 (1985).Google Scholar
  4. 4.
    Tsang, P., F. Lew, G. O’Brien, I. J. Selikoff, and J. G. Bekesi, Immunopotentiation of impaired lymphocyte functions in vitro by isoprinosine in prodromal subjects and AIDS patients, Int. J. Immunopharmacol. 7:511–514 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Tsang, P. H., K. Tangnavard, S. Solomon, and J. G. Bekesi, Modulation of T and B lymphocyte functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS), J. Clin. Immunol. 4:469–477 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    Murray, H. W., R. A. Gellene, D. M. Libby, C. D. Rothermel, and B. Y. Rubin, Activation of tissue macrophages from AIDS patients: In vitro response of AIDS alveolar macrophages to lymphokines and interferon gamma, J. Immunol. 135:2374–2377 (1985).PubMedGoogle Scholar
  7. 7.
    Koff, W. C., I. J. Fidler, S. D. Showalter, M. K. Chakraborty, B. Hampar, L. M. Ceccorulli, and E. S. Kleinerman, Human monocytes activated by immunomodulators in liposomes lyse herpesvirus infected but not normal cells, Science 224:1007–1008 (1984).PubMedCrossRefGoogle Scholar
  8. 8.
    Henney, C. S., K. Kuribayashi, D. E. Kern, and S. Gillis, Interleukin 2 augments natural killer cell activity, Nature (Lond.) 291:335–338 (1981).CrossRefGoogle Scholar
  9. 9.
    Kuribayashi, K., S. Gillis, D. E. Kern, and C. S. Henney, Murine NK cell cultures: Effects of interleukin 2 and interferon on cell growth and cytotoxic reactivity, J. Immunol. 126:2321–2327 (1981).PubMedGoogle Scholar
  10. 10.
    Hersey, P., and A. Edwards, Effect of isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo, Int. J. Immunopharmacol. 6:315–320 (1984).PubMedCrossRefGoogle Scholar
  11. 11.
    Welsh, R. M., Do natural killer cells play a role in virus infections?, Antiviral Res. 1:5–12 (1981).CrossRefGoogle Scholar
  12. 12.
    Fiorilli, M. M. Crescenzi, and F. Aiuti, Thymic hormone therapy of viral infections, Riv. Immunol. Immunoarmacol. 5:72–73 (1985).Google Scholar
  13. 13.
    Hadden, J. W., E. M. Hadden, T. Spira, R. Settineri, L. Simon, and A. Giner-Sorolla, Effects of NPT 15392 in vitro on human leukocyte functions, Int. J. Immunopharmacol. 4:235–242 (1982).PubMedCrossRefGoogle Scholar
  14. 14.
    Friedman, H., and S. Specter, Immunotherapy and immunoregulation, in: Chemotherapy of Viral Infections (P. E. Came and L. A. Caliguiri, eds.), pp. 313–330, Springer-Verlag, Berlin, (1982).CrossRefGoogle Scholar
  15. 15.
    Hadden, J. W., F. Sorice, and J. L. Touraine (eds.), Immunotherapy and viral diseases, Riv. Immunol. Immunofarmacol. 5:51–52 (1985).Google Scholar
  16. 16.
    Lagrange, P. H. Immunomodulation of bacterial infection, in: Advances in Immunopharmacology ,Vol. II (J. W. Hadden, L. Chedid, P. Dukor, F. Spreafico, and D. Wulloughby, (eds.), pp. 195–204, Pergamon London (1983).Google Scholar
  17. 17.
    Werner, G. H., Immunopotentiating substances with antiviral activity, Pharmacol. Ther. 6:235–273 (1979).CrossRefGoogle Scholar
  18. 18.
    Liu, W. T. ,R. A. Good, L. Q. Trang, R. W. Engleman, and N. K. Day, Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein Ai Association with increased circulating interferon and complement-dependent antibody, Proc. Natl. Acad. Sci. USA 81:6471–6475 (1984).PubMedCrossRefGoogle Scholar
  19. 19.
    Friedman, H., T. Klein, and R. C. Butler, Bacterial antigens as immunomodulators, in: Immunomodulation (H. H. Fudenberg, H. D. Whitten, and F. Ambrogi, (eds.), pp. 209–228, Plenum, New York (1982).Google Scholar
  20. 20.
    Suenaga, T., T. Okuyama, I. Yoshida, and M. Azuma, Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to Ectromelia virus infection: Participation of interferon in enhanced resistance, Infect. Immun. 20:312–314 (1978).PubMedGoogle Scholar
  21. 21.
    Larson, C. L., R. E. Baker, R. N. Ushijima, M. Baker, and C. A. Gillespie, Immu notherapy of Friend disease in mice employing viable BCG vaccine, Proc. Soc. Exp. Biol. Med. 140:700–702 (1972).PubMedGoogle Scholar
  22. 22.
    Ellouz, F., A. Adam, R. Ciorbaru, and E. Lederer, Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives, Biochem. Biophys. Res. Commun. 59:1317–1325 (1974).PubMedCrossRefGoogle Scholar
  23. 23.
    Chedid, L., Adjuvants for vaccines, in: Advances in Immunopharmacology ,Vol. II (J. W. Hadden, L. Chedid, P. Dukor, F. Spreafico, and D. Willoughby, (eds.), pp. 401–406, Pergamon, London (1983).Google Scholar
  24. 24.
    Audibert, F., M. Jolivet, and C. Carelli, Use of MDP with diphteric or other synthetic oligopeptides as a model for totally synthetic vaccines, in: Advances in Immunopharmacology ,Vol. II (J. W. Hadden, L. Chedid, P. Dukor, F. Smeafico, and D. Willoughby (eds.), pp. 429–434, Pergamon, London, (1983).Google Scholar
  25. 25.
    Webster, R. G., W. P. Glezen, C. Hannoun, and W. G. Laner, Potentiation of the immune response to influenza virus subunit vaccines, J. Immunol. 119:2073–2077 (1977).PubMedGoogle Scholar
  26. 26.
    Thomson, T. A., J. Hilfenhaus, H. Moser, and P. S. Morahan, Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice, Infect. Immun. 41:556–562 (1983).PubMedGoogle Scholar
  27. 27.
    Chedid, L., F. Audibert, P. Lefrancier, J. Choay, and E. Lederer, Modulation of the immune response by a synthetic adjuvant and analogs, Proc. Natl. Acad. Sci. USA 73:2472–2475 (1976).PubMedCrossRefGoogle Scholar
  28. 28.
    Butler, J. E., H. B. Richerson, P. A. Swanson, W. C. Kopp, and M. T. Suelzer, The influence of muramyl dipeptide on the secretory immune response, Ann. NY Acad. Sci. 109:669–687 (1983).CrossRefGoogle Scholar
  29. 29.
    Genco, R. J., R. Linzer, and R. T. Evans, Effect of adjuvants on orally administered antigens, Ann. NY Acad. Sci. 109:650–668 (1983).CrossRefGoogle Scholar
  30. 30.
    Taubman, M. A., J. L. Ebersole, D. J. Smith, and W. Stack, Adjuvants for secretory immune responses, Ann. NY Acad. Sci. 109:637–649 (1983).CrossRefGoogle Scholar
  31. 31.
    Morin, A., B. Chorley, and L. Chedid, Muramyl peptides in the antiviral strategy, Riv. Immunol. Immunoarmacol. 5:74–79 (1985).Google Scholar
  32. 32.
    Damais, C., G. Riveau, M. Parant, N. Gerota, and L. Chedid, Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by MDP derivative, Int. J. Immunopharmacol. 5:403–410 (1983).CrossRefGoogle Scholar
  33. 33.
    Sharma, S. D., V. Tsai, J. L. Krahenbuhl, and J. S. Remington, Augmentation of mouse natural killer cell activity by muramyl depeptide and its analogs, Cell. Immunol. 62:101 -109 (1981).PubMedCrossRefGoogle Scholar
  34. 34.
    Leclerc, C., D. Juy, E. Bourgeois, and L. Chedid, In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine. Muramyl dipeptide from MDP, Cell Immunol. 45:199–206 (1979).PubMedCrossRefGoogle Scholar
  35. 35.
    Fidler, I. J., S. Sone, W. E. Fogler, and Z. L. Barnes, Eradication of spontaneous metasta ses and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide, Proc. Natl. Acad. Sci. USA 78:1680–1684 (1981).PubMedCrossRefGoogle Scholar
  36. 36.
    Nowotny, A., (Ed.) Beneficial Effects of Endotoxins ,Plenum, New York (1983).Google Scholar
  37. 37.
    Bendinelli, M., D. Mattencci, A. M. Giangregorio, and P. G. Conaldi, Restoration of antibody responsiveness by endotoxin in retrovirus immunodepressed mice: Role of macrophages, in: Immunobiology and Immunopharmacology of Bacterial Endotoxins (A. Szentivanyi and H. Friedman, eds.), pp. 465–478, Plenum, New York (1986).Google Scholar
  38. 38.
    Friedman, H., S. Specter, and R. C. Butler, Stimulation of immunomodulatory factors by bacterial endotoxins and non-toxic polysaccharides, in: Beneficial Effects of Endotoxins (A. Nowotny, ed.), pp. 273–282, Plenum, New York (1983).CrossRefGoogle Scholar
  39. 39.
    Specter, S., M. Bendinelli, W. S. Ceglowski, and H. Friedman. Macrophage-induced reversal of immunosuppression by leukemia viruses. Macrophage functions in immunity, Fed. Proc. 37:97–101 (1978).PubMedGoogle Scholar
  40. 40.
    Finklestein, R. A., Alteration of susceptibility of embryonated eggs to Newcastle disease virus by Escherichia coli and endotoxin, Proc. Soc. Exp. Biol. Med. 106:481–484 (1961).Google Scholar
  41. 41.
    Gledhill, A. W., Sparing effect of serum from mice treated with endotoxin upon certain murine virus diseases, Nature (Lond.) 183:185–186 (1959).CrossRefGoogle Scholar
  42. 42.
    Wagner, R. R., R. M. Snyder, E. W. Hook, and C. N. Luttrell. Effect of bacterial endotoxin on resistance of mice to viral encephalitides, J. Immunol. 83:87–98 (1959).PubMedGoogle Scholar
  43. 43.
    Stiehm, E. R., Standard and special human immune serum globulins as therapeutic agents, Pediatrics 63:301–319 (1979).PubMedGoogle Scholar
  44. 44.
    Orenstein, W. A., D. L. Heymann, R.J. Ellis, R. L. Rosenberg,J. Nakano, N. A. Halsey, G. D. Overturf, G. F. Hayden, and J. J. Witte, Prophylaxis of varicella in high-risk children: Dose response effect of zoster immune globulin, J. Pediatr. 98:368–373 (1981).PubMedCrossRefGoogle Scholar
  45. 45.
    Winston, D. J., H. G. Winston, C-H. Lin, M. D. Budinger, R. E. Champlin, R. P. Gale, Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation, Am. J. Med. 76:238–133 (1984).CrossRefGoogle Scholar
  46. 46.
    Centers for Disease Control, MMWR 35:231–233 (1986).Google Scholar
  47. 47.
    McAleer, W. J., H. Z. Markus, D. E. Wampler, E. B. Buynak, W. J. Miller, R. E. Weibel, A. A. McLean, and M. R. Hilleman, Vaccine against human hepatitis B virus prepared from antigen derived from human hepatoma cells in culture (41801), Proc. Soc. Exp. Med. 175:314–319(1984).Google Scholar
  48. 48.
    Valenzuela, P., A. Medina, W. J. Rutter, G. Ammerer, and B. D. Hall, Synthesis and assembly of hepatitis B virus surface antigen particles in yeast, Nature (Lond.) 298:347–350 (1982).CrossRefGoogle Scholar
  49. 49.
    McAleer, W. J., E. B. Buynak, R. Z. Maigetter, D. E. Wampler, W. J. Miller, and M. R. Hilleman, Human hepatitis B vaccine from recombinant yeast, Nature (Lond.) 307:178–180 (1984).CrossRefGoogle Scholar
  50. 50.
    Ticehurst, J. R., Hepatitis A virus: Clones, cultures and vaccines, Semin. Liver Dis. 6:46–55 (1986).PubMedCrossRefGoogle Scholar
  51. 51.
    Buynak, E. B., R. E. Weibel, A. A. McLean, and M. R. Hilleman. Live respiratory syncytial virus vaccine administered parenterally (40112), Proc. Soc. Exp. Biol. Med. 195:636–642 (1978).Google Scholar
  52. 52.
    Buynak, E. B., R. E. Weibel, A. J. Carlson, A. A. McLean, and M. R. Hilleman. Futher investigations of live respiratory syncytial virus vaccine administered parenterally (40433), Proc. Soc. Exp. Biol. Med. 160:272–277 (1979).PubMedGoogle Scholar
  53. 53.
    Bendinelli, M., Immunomodulaton in viral infections: Virus or infection-induced? in: Immunomodulation: New Frontiers and Advances (H. H. Fugenberg, H. D. Whitten, and F. Ambrogi, eds.), pp. 161–195, Plenum, New York (1984).Google Scholar
  54. 54.
    Handzel, Z. T., Y. Burnstein, B. Rager-Zisman, and N. Trainin, The effects of thymic humoral factor (THF) on viral infection in humans, Riv. Immunol. Immunofarmacol. 5:68– 71 (1985).Google Scholar
  55. 55.
    Rager-Zisman, R. B., A. Harish, V. Rotter, Y. Yakir, and N. Trainin, Antiviral effects of THF, in: Advances in Allergy and Immunology A. Oehling, F. J. Dison, and H. G. Kunkel, eds.), pp. 25–37, Academic, New York (1980).Google Scholar
  56. 56.
    Trainin, N., V. Rotter, Y. Yakir, and R. Leve, Biochemical and biological properties of THF in animal and human models, Ann. NY Acad. Sci. 332:9–22 (1979).PubMedCrossRefGoogle Scholar
  57. 57.
    Trainin, N., M. Pecht, and Z. T. Handzel, Thymic humoral factor (THF), Immunol. Today 4:16–17 (1983).CrossRefGoogle Scholar
  58. 58.
    Dinarello, C. A., Interleukin 1, Rev. Infect. Dis. 6:52–95 (1984).CrossRefGoogle Scholar
  59. 59.
    Durum, S. K., J. A. Schmidt, and J. J. Oppenheim, IL-1: An Immunological perspective, Ann. Rev. Immunol. 3:263–87 (1985).CrossRefGoogle Scholar
  60. 60.
    Gowen, M., and G. R. Mundy, Actions of recombinant interleukin 1, interleukin 2 and interferon-gamma on bone resorption in vitro, J. Immunol. 136:2478–2482 (1986).PubMedGoogle Scholar
  61. 61.
    Dempsey, R. A., C. A. Dinarello, J. W. Mier, L. J. Rosenwasser, M. Aylegrelta, T. E. Brown, and D. R. Parkinson, The differential effects of human leukocyte pyrogen, lymphocyte activating factor, T cell growth factor and interferon on human NK activity, J. Immunol. 129:2504–2510 (1982).PubMedGoogle Scholar
  62. 62.
    Herman, J., C. A. Dinarello, M. C. Kero, and A. R. Rabson, The role of interleukin 1 in tumor NK cell interactions, correction of defective NK cell activity in cancer patients by treating target cells with interleukin 1, J. Immunol. 4:2882–2886 (1985).Google Scholar
  63. 63.
    Onozaski, K. K. Matshushima, E. S. Kleinerman, T. Saito, and J. J. Oppenheim, Role of interleukin 1 in promoting human monocyte mediated tumor cytotoxicity, J. Immunol. 135:314–320 (1985).Google Scholar
  64. 64.
    Smith, K. A., Interleukin 2, Annu. Rev. Immunol. 2:319–333 (1984).PubMedCrossRefGoogle Scholar
  65. 65.
    Erard, F., P. Corthesy, M. Nabholz, J. W. Lowenthal, P. Z., G. Plaetinck, and H. R. McDonald, Interleukin 2 is both necessary and sufficient for the growth and differentia tion of lectin-stimulated cytolytic T lymphocyte precursors, J. Immunol. 3:1644–1652 (1985).Google Scholar
  66. 66.
    Rook, A. H., H. Masur, H. Clifford, W. Frederick, T. Kasahara, A. M. Macher, J. Y. Djeu, J. F. Manischewitz, L. Jackson, A. S. Fauci, and G. V. Quinnan, Interleukin 2 enhances the depressed natural killer and cytomegalovirus-specifìc cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome,J. Clin. Invest. 72:398–403 (1983).PubMedCrossRefGoogle Scholar
  67. 67.
    Nedwin, G. E., L. P. Svedersky, T. S. Bringman, M. A. Palladino, and D. V. Goeddel, Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta, J. Immunol. 135:2492–2497 (1985).Google Scholar
  68. 68.
    Rosenberg, S. Lymphokine-activated killer cells: A new approach to immunotherapy of cancer, J. Natl. Cancer Inst. 75:595–603 (1985).PubMedGoogle Scholar
  69. 69.
    Conlon, P. J., T. L. Washkewicz, D. Y. Mochizuki, K. L. Urdal, S. Gillis, and C. S. Henney, The treatment of induced immune deficiency with interleukin 2, Immunol. Lett. 10:307–314 (1985).PubMedCrossRefGoogle Scholar
  70. 70.
    Weinberg, A. Acute genital infection in guinea pigs: Effect of recombinant interleukin 2 (rIL-2) on Herpes simplex virus-2, J. Infect. Dis. 154:134–140 (1986).PubMedCrossRefGoogle Scholar
  71. 71.
    Goeddel, D. V., D. W. Leung, T. J. Duel, M. Gross, R. M. Lawn, R. McCandliss, P. H. Seeburg, A. Ullrich, E. Yelverton, and P. W. Gray, The structure of eight distinct clone human leukocyte interferon c-DNAs, Nature (Lond.) 290:30–27 (1981).CrossRefGoogle Scholar
  72. 72.
    Nagata, S., N. Mantei, and C. Weissman, The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha, Nature (Lond.) 287:401–408 (1981).CrossRefGoogle Scholar
  73. 73.
    Gray, P. W., and D. V. Goeddel, Structure of the human immune interferon gene, Nature (Lond.) 298:859–863 (1982).CrossRefGoogle Scholar
  74. 74.
    Ohno, S., and T. Taniguehi, Structure of a chromosomal gene for human interferonbeta, Proc. Natl. Acad. Sci. USA 78:5305–5309 (1981).PubMedCrossRefGoogle Scholar
  75. 75.
    Friedman, R. A., and S. N. Vogel, Interferon with special emphasis on the immune system, Adv. Immunol. 34:97–133 (1983).sPubMedCrossRefGoogle Scholar
  76. 76.
    Stewart, W. E. II, The Interferon System ,Springer-Verlag, New York (1979).Google Scholar
  77. 77.
    Baron, S., V. Howie, M. Langford, E. M. McDonald, G. J. Stanton, J. Reitmeyer, and D. A. Wleigent, Induction of interferon by bacteria, protozoa and viruses, Defensive role, Tex. Rep. Biol. Med. 41:150–157 (1982).Google Scholar
  78. 78.
    Orn, A., H. Wigzell, A. Senik, and I. Gresser, Enhanced natural killer cell activity in mice injected with interferon and interferon inducers, Nature (Lond.) 273:759–761 (1978).CrossRefGoogle Scholar
  79. 79.
    Herberman, R. R., J. R. Ortaldo, and G. D. Bonnard, Augmentation by interferon of human natural and antibody dependent cell mediated cytotoxicity, Nature (Lond.) 277:221–223 (1979).CrossRefGoogle Scholar
  80. 80.
    Oehler, J. R., L. R. Lindsay, M. E. Nunn, H. T. Holden, and R. B. Herberman, Natural cell mediated cytotoxicity in rats. II. In vivo augmentation of natural killer cell activity, Int. J. Cancer 21:210–220 (1978).PubMedCrossRefGoogle Scholar
  81. 81.
    Oehler, J. R., and R. B. Herberman, Natural cell mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid, Int. J. Cancer ,21:221–229 (1978).PubMedCrossRefGoogle Scholar
  82. 82.
    Santoli, D., G. Trinchieri, and H. Koprowski, Cell mediated cytotoxicity against virus infected target cells in humans, J. Immunol. 121:532–538 (1978).PubMedGoogle Scholar
  83. 83.
    Targan, S., and F. Dorey, Interferon activation of prespontaneous killer cells (Pre-SK) and alteration in kinetics of lysis of both pre-SK and active SK cells, J. Immunol. 124:2157–2161 (1980).PubMedGoogle Scholar
  84. 84.
    Timonen, T., J. R. Ortaldo, and R. B. Herberman, Analysis by a single cell cytotoxicity assay of natural killer cell frequencies among human large granular lymphocytes of the effects of interferon on their activity, J. Immunol. 128:2514–2521 (1982).PubMedGoogle Scholar
  85. 85.
    Stebbing, N., Analogs of human interferons, Riv. Immunol. Immunofarmacol. 5:64–67 (1985).Google Scholar
  86. 86.
    Tyrrell, D. A. J., Interferon in the prevention and treatment of respiratory virus infec tions, Interferon Syst. 24:243–246 (1985).Google Scholar
  87. 87.
    Haglund, S., P. G. Lundquist, K. Cantell, and H. Strander, Interferon therapy in juvenile laryngeal papillomatosis, Arch. Otolaryngol. 107:327–332 (1981).PubMedCrossRefGoogle Scholar
  88. 88.
    Bomholt, A., Interferon therapy for laryngeal papillomatosis in adults, Arch. Otolaryngol. 109:550–552 (1983).PubMedCrossRefGoogle Scholar
  89. 89.
    Schonfeld, A., A. Schattner, M. Crespi, H. Levani, J. Shoham, S. Nitke, D. Wallach, T. Han, O. Yarden, T. Doerner, and M. Revel, Intramuscular human interferon-beta injections in treatment of condylomata acuminata, Lancet 1:1038–1041 (1984).PubMedCrossRefGoogle Scholar
  90. 90.
    Gresser, I., How does interferon inhibit tumor growth? Interferon 6:93–126 (1985).PubMedGoogle Scholar
  91. 91.
    Hadden, J. W., Immunomodulators in the immunotherapy of cancer and other diseases, TIPS 3:191–194 (1982).Google Scholar
  92. 92.
    DelGiacco, G. S., Levamisole, Riv. Immunol. Immunofarmacol. 5:88–91 (1985).Google Scholar
  93. 93.
    DelGiacco, G. S., F. Locci, L. Cengiarotti, E. Chessa, A. DiTucci, G. Meloni, E. Montaldo, M. Pautasso, G. Piludu, and M. C. Piras, The present status of clinical use of levamisole, in: Immunomodulation (H. H. Fudenberg, H. D. Whitten, and F. Ambrogi, eds.), pp. 303– 310, Plenum, New York (1984).CrossRefGoogle Scholar
  94. 94.
    Hadden, J. W., C. Lopez, R. J. O’Reilly, and E. M. Hadden, Levamisole and inosiplex: Antiviral agents with immunopotentiating action, Ann. NY Acad. Sci. 284:139–152 (1977).PubMedCrossRefGoogle Scholar
  95. 95.
    Talal, N., and J. Hadden, Hormones, immunomodulatory drugs, and autoimmunity, in: Handbook of Inflammation ,Vol. 5: The Pharmacology of Inflammation (I. L. Bonta, M. A. Bray, M. J. Parnham, eds.), pp. 355–369, Elsevier, New York (1985).Google Scholar
  96. 96.
    Hadden, J. W., S. Specter, A. Galy, J-L. Touraine, and E. M. Hadden, Thymic hor mones, interleukins, endotoxin, and thymomimetic drugs in T lymphocyte ontogeny, in: Advances in Immunopharmacology ,Vol. III (J. W. Hadden, L. Chedid, P. Dukor, F. Spreafico, and D. Willoughby, eds.), pp. 87–95, Pergamon, Elmsford, New York (1986).Google Scholar
  97. 97.
    Matteuci, D., A. Toniolo, P. G. Conaldi, F. Basolo, Z. Gori, and M. Bendinelli, Systemic lymphoid atrophy in coxsackie-B-3-infected mice: Effects of virus and immunopotentiating agents, J. Infect. Dis. 151:1100–1108 (1985).CrossRefGoogle Scholar
  98. 98.
    Gudvangen, R. J. ,P. S. Duffey, R. E. Paque, and C. J. Gauntt, Levamisole exacerbates coxasacki-B-3-induced murine myocarditis, Infect. Immun. 41:1157–1165 (1983).PubMedGoogle Scholar
  99. 99.
    Meade, B. D., Altered mononuclear phagocyte function in mice treated with lymphocytosis promoting factor of Bordetella pertussis, Dev. Biol. Std. 61:63–78 (1985).Google Scholar
  100. 100.
    Hewlett, E., Depression of delayed hypersensitivity responses in patients with pertussis, Dev. Biol. Std. 61:241–247 (1985).Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Mayra Lopez-Cepero
    • 1
  • Steven Specter
    • 1
  • John Hadden
    • 2
  1. 1.Department of Medical Microbiology and Immunology, College of MedicineUniversity of South FloridaTampaUSA
  2. 2.Departments of Internal Medicine and Medical Microbiology and Immunology, College of MedicineUniversity of South FloridaTampaUSA

Personalised recommendations